hydration effects glp-1 receptor agonists weight loss 2025 A preliminary study of the physiological and perceptual of during alcohol consumption in people with obesity Study finds GLP-1 receptor agonists

Phase 3 data showed 18.6% weight loss at 46 weeks

Studies have used doses ranging from 100 million to 10 billion CFU daily, with beneficial effects observed across this range

CONTRAINDICATIONS History of hypersensitivity reaction to tirzepatide or any of its excipients Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) PRECAUTIONS Kidney disease No dose adjustment is recommended in patients with any degree of renal impairment Liver disease No dose adjustment is recommended in patients with any degree of liver disease Stomach disorders Tirzepatide slows gastric emptying and is not recommended in patients with significant stomach disorders, including diabetic gastroparesis General anesthesia or deep sedation GLP-1 therapies, like tirzepatide, slow gastric emptying, possibly increasing the risk of residual gastric contents and pulmonary aspiration in patients receiving anesthesia or deep sedation for procedures

As practitioners, we must advocate for accountability not only from manufacturers but also from regulators and the broader healthcare ecosystem

PMCID: PMC12721889

For example, Vitals Apple Health integration has helped users track their meal and nutrition data